Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149781726> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2149781726 endingPage "463" @default.
- W2149781726 startingPage "460" @default.
- W2149781726 abstract "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer. Epirubicin (75 mg/m2) was given every 3 weeks and mitomycin C (10 mg/m2) every 6 weeks. Only patients with visceral involvement or with a disease-free interval of less than 12 months were considered eligible. 102 patients were evaluated for response and toxicity in the present analysis. The main sites of involvement were viscera, soft tissues, bone in 71 (69.6%), 19 (18.6%) and 12 (11.8%) patients, respectively. Multiple site involvement was present in 66 (64.7%) cases. A total of 726 courses of therapy were administered (range 2-14; mean 7.2). Follow-up ranged from 96 to 210 weeks (median follow-up 138 weeks). Response rate was complete response (CR): 21.6% [95% confidence interval (CI) +/- 0.8], partial response (PR) 49.0% (95% CI +/- 0.1), stable disease (SD) 12.7% (95% CI +/- 0.1), progressive disease (PD) 16.7% (95% CI +/- 0.1), CR + PR: 70.6% (95% CI +/- 0.1). Median values of survival and time to progression were 79.4 and 42 weeks, respectively. At 2 years, 37.2 +/- 4.7% and 12.8 +/- 3.3% of the patients, respectively, were alive or without evidence of progression. Toxicity was generally mild. One hundred and four (14.3%) cycles in 53 patients were delayed due to haematological (82) or cardiac (3) toxicity, infectious disease (11) or causes not related to the treatment (8)." @default.
- W2149781726 created "2016-06-24" @default.
- W2149781726 creator A5004612363 @default.
- W2149781726 creator A5010154213 @default.
- W2149781726 creator A5011624962 @default.
- W2149781726 creator A5013983790 @default.
- W2149781726 creator A5035683435 @default.
- W2149781726 creator A5055228504 @default.
- W2149781726 creator A5055697877 @default.
- W2149781726 date "1994-01-01" @default.
- W2149781726 modified "2023-09-25" @default.
- W2149781726 title "Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer" @default.
- W2149781726 cites W12356482 @default.
- W2149781726 cites W140895054 @default.
- W2149781726 cites W1996884189 @default.
- W2149781726 cites W2013179573 @default.
- W2149781726 cites W2052281493 @default.
- W2149781726 cites W2083902411 @default.
- W2149781726 cites W2167805334 @default.
- W2149781726 cites W2398292366 @default.
- W2149781726 cites W2401448358 @default.
- W2149781726 cites W2409194634 @default.
- W2149781726 cites W2418875927 @default.
- W2149781726 doi "https://doi.org/10.1016/0959-8049(94)90419-7" @default.
- W2149781726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7517150" @default.
- W2149781726 hasPublicationYear "1994" @default.
- W2149781726 type Work @default.
- W2149781726 sameAs 2149781726 @default.
- W2149781726 citedByCount "2" @default.
- W2149781726 crossrefType "journal-article" @default.
- W2149781726 hasAuthorship W2149781726A5004612363 @default.
- W2149781726 hasAuthorship W2149781726A5010154213 @default.
- W2149781726 hasAuthorship W2149781726A5011624962 @default.
- W2149781726 hasAuthorship W2149781726A5013983790 @default.
- W2149781726 hasAuthorship W2149781726A5035683435 @default.
- W2149781726 hasAuthorship W2149781726A5055228504 @default.
- W2149781726 hasAuthorship W2149781726A5055697877 @default.
- W2149781726 hasConcept C121608353 @default.
- W2149781726 hasConcept C126322002 @default.
- W2149781726 hasConcept C141071460 @default.
- W2149781726 hasConcept C2776694085 @default.
- W2149781726 hasConcept C2778822529 @default.
- W2149781726 hasConcept C2779338040 @default.
- W2149781726 hasConcept C2780835546 @default.
- W2149781726 hasConcept C29730261 @default.
- W2149781726 hasConcept C44249647 @default.
- W2149781726 hasConcept C530470458 @default.
- W2149781726 hasConcept C71924100 @default.
- W2149781726 hasConcept C90924648 @default.
- W2149781726 hasConceptScore W2149781726C121608353 @default.
- W2149781726 hasConceptScore W2149781726C126322002 @default.
- W2149781726 hasConceptScore W2149781726C141071460 @default.
- W2149781726 hasConceptScore W2149781726C2776694085 @default.
- W2149781726 hasConceptScore W2149781726C2778822529 @default.
- W2149781726 hasConceptScore W2149781726C2779338040 @default.
- W2149781726 hasConceptScore W2149781726C2780835546 @default.
- W2149781726 hasConceptScore W2149781726C29730261 @default.
- W2149781726 hasConceptScore W2149781726C44249647 @default.
- W2149781726 hasConceptScore W2149781726C530470458 @default.
- W2149781726 hasConceptScore W2149781726C71924100 @default.
- W2149781726 hasConceptScore W2149781726C90924648 @default.
- W2149781726 hasIssue "4" @default.
- W2149781726 hasLocation W21497817261 @default.
- W2149781726 hasLocation W21497817262 @default.
- W2149781726 hasOpenAccess W2149781726 @default.
- W2149781726 hasPrimaryLocation W21497817261 @default.
- W2149781726 hasRelatedWork W1484554393 @default.
- W2149781726 hasRelatedWork W1884490053 @default.
- W2149781726 hasRelatedWork W1984253027 @default.
- W2149781726 hasRelatedWork W2028269442 @default.
- W2149781726 hasRelatedWork W2152593810 @default.
- W2149781726 hasRelatedWork W2159759416 @default.
- W2149781726 hasRelatedWork W2357863562 @default.
- W2149781726 hasRelatedWork W2376759146 @default.
- W2149781726 hasRelatedWork W2377624260 @default.
- W2149781726 hasRelatedWork W2410959598 @default.
- W2149781726 hasVolume "30" @default.
- W2149781726 isParatext "false" @default.
- W2149781726 isRetracted "false" @default.
- W2149781726 magId "2149781726" @default.
- W2149781726 workType "article" @default.